INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

Core Viewpoint - INmune Bio Inc. is set to present top line data from the Phase 2 MINDFuL trial focused on early Alzheimer's Disease during a conference call on June 30, 2025 [1][2]. Group 1: MINDFuL Trial Details - The MINDFuL trial is an international, blinded, randomized Phase 2 study involving patients with early Alzheimer's Disease (AD) who exhibit biomarkers of elevated neuroinflammation [3]. - Participants in the trial must have at least one of four inflammation biomarkers: elevated CRP, HgbA1c, ESR, or ApoE4 allele, and they receive either XPro™ or placebo in a 2:1 ratio for 6 months [3]. - Cognitive endpoints for the trial include EMACC and CDR, with XPro™ administered as a once-a-week subcutaneous injection [3]. Group 2: XPro™ Overview - XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that selectively neutralizes soluble TNF without affecting trans-membrane TNF or TNF receptors [4]. - The drug aims to reduce neuroinflammation, potentially benefiting patients with neurological diseases [4]. Group 3: Company Background - INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments targeting the innate immune system [5]. - The company has three product platforms, including the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, which is in clinical trials for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [5][6]. - Other platforms include the Natural Killer Cell Priming Platform and the CORDStrom™ program, which targets chronic inflammation and cancer [5][6].